Vidant Oncology-Kinston

Summary

Vidant Oncology-Kinston is a medical facility located in Kinston, North Carolina. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other specialties. Vidant Oncology-Kinston is involved with conducting 115 clinical trials across 246 conditions. There are 1 research doctors associated with this hospital, such as Misbah U. Qadir.

Top PIs

Clinical Trials running at Vidant Oncology-Kinston

Multiple Myeloma

Lung Cancer

Prostate Cancer

Pancreatic Cancer

Oropharyngeal Carcinoma

Chronic Lymphocytic Leukemia

Oral Squamous Cell Carcinoma

Throat Cancer

Laryngeal Squamous Cell Carcinoma

Cancer

Lenalidomide + Dexamethasone +/- Daratumumab

for Multiple Myeloma

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

Recruiting

2 awards

Phase 3

12 criteria

Combination Therapy

for Multiple Myeloma

This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.

Recruiting

2 awards

Phase 3

32 criteria